Next Article in Journal
Burden of Rare Variants in ALS and Axonal Hereditary Neuropathy Genes Influence Survival in ALS: Insights from a Next Generation Sequencing Study of an Italian ALS Cohort
Next Article in Special Issue
The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management
Previous Article in Journal
Mechanisms of Blood–Brain Barrier Dysfunction in Traumatic Brain Injury
Previous Article in Special Issue
Aberrant Expression of RAD52, Its Prognostic Impact in Rectal Cancer and Association with Poor Survival of Patients
Review

An Immunological Glance on Pancreatic Ductal Adenocarcinoma

1
Department of Urology, Ulm University Hospital, 89081 Ulm, Germany
2
Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to the work.
Int. J. Mol. Sci. 2020, 21(9), 3345; https://doi.org/10.3390/ijms21093345
Received: 12 March 2020 / Revised: 23 April 2020 / Accepted: 6 May 2020 / Published: 8 May 2020
(This article belongs to the Special Issue Biological Interfaces in Gastrointestinal Cancer)
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Different factors such as mutational landscape, intra- and intertumoral heterogeneity, stroma, and immune cells impact carcinogenesis of PDAC associated with an immunosuppressive microenvironment. Different cell types with partly opposing roles contribute to this milieu. In recent years, immunotherapeutic approaches, including checkpoint inhibitors, were favored to treat cancers, albeit not every cancer entity exhibited benefits in a similar way. Indeed, immunotherapies rendered little success in pancreatic cancer. In this review, we describe the communication between the immune system and pancreatic cancer cells and propose some rationale why immunotherapies may fail in the context of pancreatic cancer. Moreover, we delineate putative strategies to sensitize PDAC towards immunological therapeutics and highlight the potential of targeting neoantigens. View Full-Text
Keywords: PDAC; immunotherapy; pancreatic cancer; immune checkpoints; immune microenvironment PDAC; immunotherapy; pancreatic cancer; immune checkpoints; immune microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Melzer, M.K.; Arnold, F.; Stifter, K.; Zengerling, F.; Azoitei, N.; Seufferlein, T.; Bolenz, C.; Kleger, A. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci. 2020, 21, 3345. https://doi.org/10.3390/ijms21093345

AMA Style

Melzer MK, Arnold F, Stifter K, Zengerling F, Azoitei N, Seufferlein T, Bolenz C, Kleger A. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2020; 21(9):3345. https://doi.org/10.3390/ijms21093345

Chicago/Turabian Style

Melzer, Michael K., Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Christian Bolenz, and Alexander Kleger. 2020. "An Immunological Glance on Pancreatic Ductal Adenocarcinoma" International Journal of Molecular Sciences 21, no. 9: 3345. https://doi.org/10.3390/ijms21093345

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop